Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimer's and Parkinson's...

Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimer's and
Parkinson's Diseases at AAN Annual Meeting

Collaboration with Noted Neurologists to Plan Next Clinical Studies

OMAHA, Neb. and HOUSTON, May 11 /PRNewswire-FirstCall/ -- Transgenomic, Inc.
(OTC Bulletin Board: TBIO) and Power3 Medical Products, Inc. (OTC Bulletin
Board: PWRM), announced the clinical introduction of the NuroPro(R) AD and
NuroPro(R) PD tests for Alzheimer's and Parkinson's disease at the 2009
American Academy of Neurology meeting in Seattle, WA. The NuroPro tests help
clinicians distinguish patients with Alzheimer's and Parkinson's diseases from
"normal" individuals and patients with other neurological disorders. The
tests, developed by Power3, are a panel of blood serum protein biomarkers
evaluated by biostatistical analysis to predict the probability a patient has
neurodegenerative disease. This information will help physicians make earlier
diagnoses and recommend appropriate follow-up and treatment options for their
patients.

Katerina Marcopoulou, M.D., Assistant Professor of Neurology at the University
of Thessaly, Greece, gave a platform presentation of Phase I results of a
prospective Parkinson's disease trial of NuroPro PD at the AAN meeting. Her
presentation covered data developed as part of the clinical validation of
NuroPro PD being conducted at the University of Thessaly. The results
demonstrated that NuroPro PD was able to discriminate between Parkinson's
disease patients and age-matched control subjects with a sensitivity of 93%
and specificity of 96%. In addition, samples from North American Parkinson's
disease patients were correctly identified with 100% sensitivity when tested
against the Greek patient database. Dr. Marcopoulou also presented data
correlating blood serum concentrations of some of the key protein biomarkers
utilized in the NuroPro PD assay with the severity of Parkinson's disease as
measured by two separate clinical scoring methods.

Through a collaboration/licensing agreement between Transgenomic, which
develops and provides molecular diagnostic tests and instruments for genetic
analysis, and Power3, independent validation of test results for both
Alzheimer's and Parkinson's diseases are being conducted with key clinical
centers. At the AAN meeting, Power3's Scientific Advisory Board met to plan
the next phase of key validation trials. The Scientific Advisory Board
currently includes Stanley H. Appel, M.D. Chair of Neurology at Methodist
Neurological Research Institute in Houston, TX, Marwan Sabbagh, M.D., Medical
Director of the Banner Sun Health Research Institute in Sun City, AZ and
principal investigator of the Alzheimer's study, Bruce Chase, PhD,
Neuroscientist and Professor of Biology at the University of Nebraska, Omaha
and Dr. Marcopoulou.

"This is the first formal announcement from Transgenomic and Power3 of the
clinical introduction of the NuroPro blood test for Alzheimer's and
Parkinson's Diseases. The presentation of successful Phase I validation of
NuroPro for Parkinson's disease was performed using blood serum from patients,
in the same way that the test will be performed in a clinical diagnostic
setting. The statistically significant results achieved in comparing samples
from non-diseased age-matched controls to those from mild, moderate, and
severe Parkinson's disease demonstrated the diagnostic capability of NuroPro
PD at this prestigious meeting," said Power 3's President and Chief Scientific
Officer, Dr. Ira L. Goldknopf.

"The agreement with Transgenomic, the progress of the clinical validation
achieved to date and the introduction at the AAN meeting are steps toward our
goal to be the first to market with clinically relevant diagnostic tests for
Alzheimer's and Parkinson's diseases," commented Helen R. Park, CEO of
Power3.

Craig Tuttle, President and CEO of Transgenomic, added: "We are excited to see
this first key clinical validation milestone for the NuroPro PD assay in
Parkinson's disease announced at a major neurology conference. The
observation that we may be able to quantify disease severity may prove
instrumental in allowing better therapy selections, as well as having therapy
initiated more quickly. We remain committed to launching these assays in our
CLIA-certified reference lab before the end of the year."

About Power3 Medical Products, Inc.
Power3 Medical Products (OTC BB: PWRM, www.power3medical.com) is a leader in
bio-medical research and the commercialization of neurodegenerative disease
and cancer biomarkers, pathways, and mechanisms of diseases through the
development of diagnostic tests and drug targets. Power3's patent-pending
technologies are being used to develop screening and diagnostic tests for the
early detection and prognosis of disease, identify protein biomarkers, and
drug targets, and its diagnostic tests are targeted toward markets with
critical unmet needs in areas including neurodegenerative disease (NuroPro)
and breast cancer (BC-SeraPro). Power3 expects to complete phase II clinical
validation trials of its blood serum diagnostics for Alzheimer's and
Parkinson's disease (NuroPro AD and PD), in the fourth quarter of 2009,
followed by completion of filing with the FDA. Power3 operates a
state-of-the-art CLIA certified laboratory in The Woodlands (Houston), and
continues to evolve and enhance its IP portfolio, employing sensitive and
specific combinations of biomarkers it has discovered from a broad range of
diseases as the basis of highly selective blood-based tests for ALS,
Alzheimer's, and Parkinson's diseases, breast cancer, and drug resistance.

About Transgenomic
Transgenomic is a global biotechnology company that provides unique products
and services for automated high sensitivity genetic variation and mutation
analysis. Their offerings include systems, products, discovery and laboratory
testing services to the academic and medical research, clinical laboratory and
pharmaceutical markets in the fields of Pharmacogenomics and personalized
medicine. Specific offerings include WAVE(R) DHPLC Systems, related
consumables and assay kits, Cytogenetics automated systems, and Transgenomic
Pharmacogenomics and Reference Laboratory Services. Transgenomic
Pharmacogenomics and Laboratory Services utilize their technology and
expertise to provide a menu of mutation scanning tests for over 700
cancer-associated genes and more than 60 validated diagnostic tests to meet
the needs of pharmaceutical and biotech companies, research and clinical
laboratories, physicians and patients. For more information about the
innovative systems, products and services offered by Transgenomic, please
visit: www.transgenomic.com.

Cautionary Statements
Certain statements in this press release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements include, but are not limited to, those
with respect to management's current views and estimates of future economic
circumstances, industry conditions, company performance and financial results,
including the ability of the Company to grow its involvement in the diagnostic
products and services markets. The known risks, uncertainties and other
factors affecting these forward-looking statements are described from time to
time in reports to the Securities and Exchange Commission. Any change in such
factors, risks and uncertainties may cause the actual results, events and
performance to differ materially from those referred to in such statements.
Accordingly, the company claims the protection of the safe harbor for
forward-looking statements contained in the Private Securities Litigation
Reform Act of 1995 with respect to all statements contained in this press
release.

SOURCE Transgenomic, Inc.

Debra Schneider, Chief Financial Officer of Transgenomic, Inc.,
+1-402-452-5400, investorrelations@transgenomic.com